Document:

Employment Agreement between Furiex Pharm. and Marshall Woodworth

 Exhibit 10.19 

EMPLOYMENT AGREEMENT 

THIS EMPLOYMENT AGREEMENT (the “Agreement”), is made and entered into on this
29th day of January, 2010, to be effective on the 29th day
of January, 2010 (the “Effective Date”), by and between PPD Therapeutics, Inc., a Delaware corporation (the “Company”), with its principal place of business in North Carolina and currently with a mailing address for notice
purposes of 929 North Front Street, Wilmington, North Carolina 28401, Attention: President, and Marshall Woodworth (“Employee”), an individual whose mailing address for notice purposes is 503 Middenhall Way, Cary, North Carolina 27513.

 RECITALS 

A. Before Employee and the Company entered into this Agreement, Pharmaceutical Product Development, Inc. (“PPDI”) announced its
plan to spin off its compound partnering business into a separate, publicly-traded entity (the “Spin-Off”). 
 B. The
Company is a wholly-owned subsidiary of PPDI and was formed for the purpose of owning and operating PPDI’s compound partnering business prior to and after the Spin-Off. 

C. PPDI and the Company currently anticipate that the Spin-Off will be accomplished through a pro rata dividend of all of the common
stock of the Company to the shareholders of PPDI and will be completed by mid-2010. 
 D. The Company desires to employ Employee
and Employee desires to be employed by the Company, all upon the terms and conditions set forth herein. 
 NOW,
THEREFORE, in consideration of the foregoing recitals, the mutual covenants of the parties hereinafter set forth and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as
follows: 
 ARTICLE 1 

EMPLOYMENT AND DUTIES 

1.1 Employment of Employee. On the Effective Date, the Company agrees to employ Employee and Employee accepts such employment
pursuant and subject to the terms and conditions of this Agreement. 
 1.2. Duties and Powers. During the Employment
Period (as defined herein), Employee shall serve as Vice President-Finance of the Company and Company’s principal financial officer for purposes of Securities and Exchange Commission reporting and will have such responsibilities, duties and
authority, and will render such services for and in connection with the Company and its affiliates as are customarily performed by the head financial officer of a publicly-traded company and as the Board of Directors of the

 
Company (the “Board”) and the President of the Company shall from time to time reasonably direct. Employee shall devote Employee’s full business time and attention exclusively to
the Business of the Company and shall use best efforts to faithfully carry out Employee’s duties and responsibilities hereunder. Employee shall comply with all personnel policies and procedures of the Company as the same now exist or may be
hereafter implemented by the Company from time to time, including those policies contained in the Company’s employee manual or handbook which sets forth policies and procedures generally for employees of the Company and its current or future
subsidiaries (the “Handbook”) to the extent not inconsistent with this Agreement. 
 ARTICLE 2 

TERM OF EMPLOYMENT 

Unless sooner terminated as provided elsewhere in this Agreement, Employee’s employment under this Agreement shall begin the
Effective Date and end on the first anniversary thereof (“Initial Employment Period”). After the Initial Employment Period, this Agreement shall automatically renew for successive one-year periods, unless either the Company or Employee
provides written notice to the other at least ninety (90) days prior to the termination of the Initial Employment Period or any renewal period stating said party’s desire to terminate this Agreement. The Initial Employment Period and any
extension or renewal thereof shall be referred to herein together as the “Employment Period”. Notwithstanding anything to the contrary contained herein, the Employment Period is subject to termination pursuant to Article 4 hereof.

 ARTICLE 3 

COMPENSATION AND BENEFITS 

3.1 Base Salary. During the Employment Period, the Company will pay Employee an annual base salary at a rate of $220,000 per annum
(the “Base Salary”), payable in accordance with the Company’s regular payroll policy for salaried employees. The Base Salary of Employee may be subject to periodic review and adjustment by the Company during the Employment Period. If
the Employment Period is terminated pursuant to Article 4 hereof or is otherwise shorter than a full contract year, then the Base Salary for any partial year will be prorated based on the number of days elapsed in such year during which services
were actually performed by Employee. 
 3.2 Benefits. 

a. From the Effective Date until the Spin-Off is complete, during the Employment Period, Employee will be entitled to
participate in the group health insurance and other benefits offered by PPDI and available to Company employees, subject to Employee meeting the eligibility requirements for such PPDI plans and benefits. After the Spin-Off, during the Employment
Period, Employee will no longer be entitled to participate in the PPDI plans and benefits, but will be entitled to participate in the Company’s plans and benefits as such plans and benefits are maintained from time to time by the Company,
subject again to Employee meeting the applicable eligibility criteria therefor. Nothing in this Agreement will be interpreted to alter PPDI’s or the 

 

 2 

 
Company’s right to amend, modify or terminate any such plans and benefits in its discretion from time to time. During the Employment Period, Employee will also be entitled to twenty-two
(22) days of paid time off, subject to the provisions of the Company’s Handbook or any other written policy of the Company on paid time off. 

b. In addition to the benefits provided in (a), above, during the Employment Period, Employee will be eligible to
participate in the Company’s discretionary annual cash incentive plan (the “Cash Incentive Plan”), once adopted and established by the Company’s Board or a committee thereof. Subject to the Company establishing and implementing
the Cash Incentive Plan, the Company anticipates that the target bonus for Employee’s position in 2010 will be thirty percent (30%) of Employee’s Base Salary earned in that calendar year. Awards under the Cash Incentive Plan, if any,
will be based upon both the Company’s achievement of its corporate and financial goals and Employee’s individual performance, and are entirely at the Company’s discretion. To receive any award under the Cash Incentive Plan, Employee
must be actively employed by the Company on the date payments are made under the Cash Incentive Plan. 
 3.3 Equity
Compensation. Subject to the adoption of an equity compensation plan by the Company’s Board (the “Equity Plan”), Employee shall be eligible to participate in such Plan during the Employment Period. Subject to the approval by the
Company’s Board or committee thereof, the Company shall grant to Employee incentive options to purchase shares equal to 0.25% of the Company’s outstanding common stock on or before the expiration of the sixty (60) day period following
the Spin-Off (the “Initial Option Grant”). The Initial Option Grant shall be subject to the terms and conditions of the Equity Plan and such other stock option award agreements and/or terms and conditions as the Company’s Board shall
require. In addition, the Initial Option Grant shall be subject to a three year linear vesting schedule under which one-third of the total number of options granted under the Initial Option Grant shall vest on the first, second and third
anniversaries of the Effective Date. The Initial Option Grant shall have an exercise price based on the fair market value of the Company’s common stock on the date of grant as measured in the manner established by the Company’s Board or
committee thereof. 
 3.4 Expenses. During the Employment Period, the Company will reimburse Employee, in accordance with
and subject to Employee’s compliance with the Company’s policy, for Employee’s necessary and reasonable out-of-pocket expenses incurred in the course of performance of Employee’s duties hereunder. All reimbursement of expenses to
Employee hereunder shall be conditioned upon Employee’s presentation of timely and sufficient documentation evidencing such expenses, in accordance with the Company’s policies and procedures on business expense reimbursement. 

3.5 Working Facilities. Employee shall work out of the Company’s principal offices in Morrisville, North Carolina. The
Company shall furnish Employee with such office space, equipment, technical, secretarial and clerical assistance and such other facilities, services and supplies as shall be reasonably necessary to enable Employee to perform the duties required of
Employee hereunder in an efficient and professional manner. 
  

 3 

 ARTICLE 4 

TERMINATION OF EMPLOYMENT 

4.1 Basis for Termination. Notwithstanding any other provision in this Agreement to the contrary, the Employment Period and
Employee’s employment hereunder shall terminate effective on the date indicated upon the happening of any of the following events: 

a. Upon the death of Employee, effective immediately on the date of death without any notice; 

b. Upon Employee’s inability to perform the essential functions of his position for a period of (i) ninety
(90) consecutive days, or (ii) ninety (90) nonconsecutive days within a six (6) month period (exclusive of any leave Employee may take under the Family and Medical Leave Act, 29 U.S.C. § 12101 et seq.), due to a physical or
mental impairment which is determined to be total and permanent by a physician selected and retained by Company and acceptable to the Employee or the Employee’s legal representative, and subject to Company’s full compliance with its
obligations under the Americans with Disabilities Act, 29 U.S.C. § 2601 et seq., including, but not limited to, its obligation to offer reasonable accommodation to Employee, effective as of the first business day after the expiration of the
ninety (90) day or six (6) month period specified above, whichever is applicable; or 
 c. Upon a
determination by the President, acting in good faith but made in his or her sole discretion, that Employee: (i) willfully refused to make a reasonable good faith effort to perform Employee’s duties under this Agreement; (ii) failed to
cure material deficiencies in Employee’s performance to the reasonable satisfaction of Company within thirty (30) days following Employee’s receipt of written notice from Company which specifically identifies the manner in which the
Company alleges Employee’s performance of duties has been materially deficient; (iii) misappropriated or embezzled any tangible or intangible property of the Company; (iv) willfully or intentionally committed a material violation of
any Company policy or procedure, including, but not limited to, engaging in any form of discrimination or harassment prohibited by law; (v) willfully or intentionally committed an act or omission with the intent to cause harm to Company, or is
determined in good faith by the Company to be materially and demonstrably injurious to Company’s reputation or business; (vi) has been convicted or pled guilty or no contest to any felony; or (vii) failed to cure Employee’s
material breach of this Agreement to Company’s reasonable satisfaction within thirty (30) days of Employee’s receipt of written notice from Company which specifically identifies the manner in which the Company alleges Employee
breached the Agreement. 
 Upon a determination by the President, acting in good faith but made in his or her sole discretion,
that Employee: (i) failed to substantially perform Employee’s duties and responsibilities for the Company and/or committed a material violation of any Company policy or procedure (including without limitation any policy or procedure
described in the Handbook); (ii) willfully, intentionally or negligently engaged in any act or omission that 
  

 4 

 
injures, or, in the opinion of the Board, has the capacity to injure, the business or reputation of the Company, including but not limited to injury to any director, employee, client or
shareholder of the Company; (iii) demonstrated negligence and/or willful misconduct in Employee’s execution of duties for the Company (including but not limited to insubordination); (iv) engaged in a form of discrimination or
harassment prohibited by law (including, without limitation, discrimination or harassment based on race, color, religion, sex, national origin, age, disability, and/or genetic information); (v) misappropriated or embezzled any tangible or
intangible property of the Company; (vi) breached the terms of this Agreement and/or any other written agreement between Employee and the Company; and/or (vii) has been indicted on charges of, convicted of or pleaded guilty or no contest
to a felony. 
 4.2 Compensation After Termination During Employment Period. If the Company terminates Employee’s
employment during the Employment Period pursuant to Section 4.1 hereof or if either party terminates this Agreement pursuant to Article 2 hereof, then the Company shall have no further obligations hereunder or otherwise with respect to
Employee’s employment from and after the termination or expiration date, except that the Company shall pay Employee’s Base Salary accrued through the date of termination or expiration and shall provide such benefits as are required by
applicable law. From and after such termination or expiration date, the Company shall continue to have all other rights available hereunder, including without limitation all rights under the Proprietary Agreement and/or the Non-Competition Agreement
(as hereinafter defined) and attached hereto as Annex A and Annex B, respectively. 
 4.3 Resignation as
Officer and Director. Upon termination of Employee’s employment by either party for any reason, Employee will also be deemed to have resigned his or her position(s), if any, as an officer or director of the Company, as a member of any Board
committees, as well as any other positions he or she may hold with or for the benefit of the Company and/or its affiliates. 

ARTICLE 5 

PROPRIETARY INFORMATION 

Prior to or coincident with the Effective Date, Employee shall execute and deliver to the Company its standard Proprietary Information
and Inventions Agreement (the “Proprietary Agreement”), a copy of which is attached hereto as Annex A. 

ARTICLE 6 

NON-COMPETITION AND NON-SOLICITATION 

Prior to or coincident with the Effective Date, Employee shall execute and deliver to the Company its standard Non-Competition and
Non-Solicitation Agreement (the “Non-Competition Agreement”), a copy of which is attached hereto as Annex B. 
  

 5 

 ARTICLE 7 

MISCELLANEOUS 

7.1 Withholding Taxes. All amounts payable under this Agreement, whether such payment is to be made in cash or other property,
shall be subject to applicable withholding requirements for Federal, state and local income taxes, employment and payroll taxes, and other legally required withholding taxes and contributions to the extent appropriate in the determination of the
Company, and Employee shall report all such amounts as income on Employee’s personal income returns and for all other purposes. 

7.2 Assignment. No party hereto may assign or delegate any of its rights or obligations hereunder without the prior written
consent of the other party hereto; provided, however, that the Company shall have the right to assign all or any part of its rights and obligations under this Agreement (i) to any member, subsidiary or affiliate of the Company or any surviving
entity following any merger or consolidation of any of those entities with any entity other than the Company, or (ii) in connection with the sale of all or substantially all of the Company’s assets.  

7.3 Binding Effect. All covenants and agreements contained in this Agreement by or on behalf of any of the parties hereto shall be
binding upon and inure to the benefit of the respective legal representatives, heirs, successors and permitted assigns of the parties hereto. 

7.4 Entire Agreement. This Agreement (including the Proprietary Agreement and Non-Competition Agreement attached hereto as
Annexes A and B) sets forth the entire understanding of the parties and supersedes and preempts all prior oral or written understandings and agreements with respect to the subject matter hereof. 

7.5 Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the
remainder of this Agreement. 
 7.6 Amendment; Modification. No amendment or modification of this Agreement and no waiver
by any party of the breach of any covenant contained herein shall be binding unless executed in writing by the party against whom enforcement of such amendment, modification or waiver is sought. No waiver shall be deemed a continuing waiver or a
waiver in respect of any subsequent breach or default, either of a similar or different nature, unless expressly so stated in writing. 

7.7 Governing Law. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of
North Carolina, without giving effect to provisions thereof regarding conflict of laws. 
  

 6 

 7.8 Arbitration. Except for disputes, controversies or claims arising out of or
related to the Proprietary Agreement and/or the Non-Competition Agreement attached as Annex A and B, respectively, any dispute, controversy or claim arising out of or relating to this Agreement, including but not limited to its
existence, validity, interpretation, performance or non-performance or breach, shall be decided by a single neutral arbitrator agreed upon by the parties hereto in Raleigh, North Carolina in binding arbitration pursuant to the commercial arbitration
rules of the American Arbitration Association then in effect. The parties to any such arbitration shall be limited to the parties to this Agreement or any successor thereof. The written decision of the arbitrator shall be final and binding and may
be entered and enforced in any court of competent jurisdiction. Each party waives any right to a jury trial in any such forum. Each party to the arbitration shall pay its fees and expenses, unless otherwise determined by the arbitrator. 

7.9 Notices. All notices, demands or other communications to be given or delivered hereunder or by reason of the provisions of
this Agreement shall be in writing and shall be deemed to have been properly served if (a) delivered personally, (b) delivered by a recognized overnight courier service, (c) sent by certified mail, return receipt requested and first
class postage prepaid, or (d) sent by facsimile transmission followed by a confirmation copy delivered by a recognized overnight courier service the next day. Such notices, demands and other communications shall be sent to the address first set
forth above, or to such other address or to the attention of such other person as the recipient party has specified by prior written notice to the sending party. Date of service of such notice shall be (i) the date such notice is personally
delivered or sent by facsimile transmission (with issuance by the transmitting machine of a confirmation of successful transmission), (ii) the date of receipt if sent by certified mail, or (iii) the date of receipt if sent by overnight
courier. 
 7.10 Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an
original and all of which taken together shall constitute one and the same agreement. 
 7.11 Descriptive Heading;
Interpretation. The descriptive headings in this Agreement are inserted for convenience of reference only and are not intended to be part of or to affect the meaning or interpretation of this Agreement. 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written. 

 

							
	COMPANY:  	 		 	PPD THERAPEUTICS, INC.
				
		 		 	By:	 	 
		 		 	Name:	 	 
		 		 	Title:	 	 
		 		 	
			
	EMPLOYEE:	 		 	  

		 		 	Marshall Woodworth

  

 7 

 ANNEX A 

PROPRIETARY INFORMATION 

AND INVENTIONS AGREEMENT 

In consideration and as a condition of my employment by PPD Therapeutics, Inc., a Delaware corporation with its principal place of
business in Wake County, North Carolina, or any affiliate, subsidiary, successor or assigns, as the case may be (collectively referred to herein as the “Company”), I hereby agree as follows: 

1. “Proprietary Information” is information that was or is developed by, became or becomes known by, or was or is assigned or
otherwise conveyed to the Company, and which has commercial value in the Company’s business. Proprietary Information includes, without limitation, trade secrets, financial information, product plans, customer lists, marketing plans and
strategies, systems, manuals, forecasts and other business information, improvements, inventions, business strategies, business methods and practices, formulas, product ideas, biological material and techniques for their handling and use, chemical
and/or information analysis and related products and data, computer programs and software, software designs and documentation, source codes, algorithms, techniques, schematics, know-how and data, and any other confidential or proprietary information
of the Company or its customers or clients which I have been, or may be exposed to, or have learned or may learn of from time to time in connection with or as a result of my capacity as an employee of or consultant to the Company, including during
the term of this Agreement. Proprietary Information shall not include information that is, through no improper action or inaction by me, generally available to the public. I understand that my employment creates a relationship of confidence and
trust between me and the Company with respect to Proprietary Information of the Company or its customers which may be learned by me during the period of my employment. 

2. In consideration of my employment by the Company and the compensation received by me from the Company from time to time, I hereby
agree as follows: 
 (a) All Proprietary Information and all patents, copyrights, trade secret rights and other
rights (including throughout, without limitation, any extensions, renewals, continuations or divisions of any of the foregoing) in connection therewith shall be the sole property of the Company. I hereby assign to the Company any rights I may have
or acquire in such Proprietary Information. At all times, both during my employment by the Company and after its termination, I will keep in confidence and trust and will not use or disclose any Proprietary Information or anything relating to it
without the written consent of the Company, except as may be necessary in the ordinary course of performing my duties to the Company. 

(b) In the event of the termination of my employment by me or by the Company for any reason, I shall return all documents,
records, apparatus, equipment and other physical property, or any reproduction of such property, whether or not pertaining to Proprietary Information, furnished to me by the Company or produced by myself or others in connection with my employment,
to the Company immediately as and when requested by the Company. 

 (c) I will promptly disclose to the Company, or any persons designated by
it, all “Inventions”, which includes all improvements, inventions, formulas, ideas, works of authorship, processes, computer programs and software, software designs and documentation, algorithms, techniques, schematics, know-how data,
whether or not patentable, made or conceived or reduced to practice or developed by me, either alone or jointly with others, during the term of my employment and for six (6) months thereafter. To the extent the Company does not have rights
therein hereunder, such disclosure shall be received by the Company in confidence and does not extend the assignment made in Section (d) below. 

(d) I agree that all Inventions which I make, conceive, reduce to practice or develop (in whole or in part, either alone
or jointly with others) during my employment shall be the sole property of the Company to the maximum extent permitted by law, and, to the extent permitted by law, shall be “works made for hire”. The Company shall be the sole owner of all
patents, copyrights, trade secret rights, and other intellectual property or other rights in connection therewith. I hereby assign to the Company any rights I may have or acquire in such Inventions. I agree to perform, during and after my
employment, all acts deemed necessary or desirable by the Company to permit and assist it, at the Company’s expense, in obtaining and enforcing patents, copyrights, trade secret rights or other rights on such Inventions and/or any other
Inventions I have or may at any time assign to the Company in any and all countries. Such acts may include, but are not limited to, execution of documents and assistance or cooperation in legal proceedings. With respect to any and all matters
arising out of or relating to my employment or consultancy with the Company, I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents, as my agents and attorneys-in-fact to act for and in my behalf and
instead of me, to execute and file any applications or related filings and do all other lawfully permitted acts to further the prosecution and issuance of patents, copyrights, trade secret rights or other rights thereon with the same legal force and
effect as if executed by me. 
 (e) I attach hereto a complete list of all Inventions or improvements to which I
claim ownership and/or that I desire to remove from the operation of this Agreement, and I covenant that such list is complete. If no such list is attached to this Agreement, I represent that I have no such Inventions and improvements at the time of
signing this Agreement. I understand that any such list shall not contain information that breaches an obligation of confidentiality with a former employer. 

(f) I represent that my performance of all the terms of this Agreement will not breach any agreement or obligation to keep
in confidence proprietary information acquired by me in confidence or in trust prior to my employment by the Company. I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict herewith or in
conflict with my employment with the Company. 
  

 2 

 3. The Company agrees that it will not request as part of my employment that I divulge or
make use of proprietary information of any of my former employers that has commercial value to the former employer who developed such information. 

4. I acknowledge that in the event of my breach or threatened breach of the terms of this Agreement, the Company shall not have an
adequate remedy at law and shall, in addition to any other available rights and remedies, have the right to obtain injunctive relief, including without limitation specific performance. 

5. This Agreement shall be effective as of the first day of my employment by the Company, and shall be binding upon me, my heirs,
executors, assigns, and administrators, and shall inure to the benefit of the Company and any current and future affiliates, subsidiaries, successors and assigns. This Agreement supersedes any agreement which may have been previously made or
executed by me relating to this matter. This Agreement shall be governed by the laws of the State of North Carolina (exclusive of conflicts of law provisions), which shall be the venue for resolution of any dispute related to this Agreement. This
Agreement or any part thereof shall not be modified, amended, or waived except by the written consent of the Company’s Chief Executive Officer or President. 
  

					
		
	Dated:	 	                         ,
20    
		
		 	  

		 	Marshall Woodworth
	
	Accepted and Agreed to:
		
		 	PPD Therapeutics, Inc.
			
		 	By:	 	 
		 	Name:	 	 
		 	Title:	 	 

  

 3 

 ANNEX B 

NON-COMPETITION AND 

NON-SOLICITATION AGREEMENT 

THIS AGREEMENT is made this          day of
                    , 2010, by and between PPD Therapeutics, Inc., a Delaware corporation with its principal place in North Carolina (the
“Company”), and Marshall Woodworth, an individual whose address is 503 Middenhall Way, Cary, North Carolina 27513 (herein referred to as “Employee”). 

RECITALS 

A. The Company is engaged in the business of developing and commercializing, directly and with third parties, potential drug candidates
and drug products in various therapeutic areas (the “Business”). 
 B. Employee will perform a highly responsible role
in the Company’s organization, have specialized knowledge of the Company’s Business, existing and future potential drug candidates and drug products, and trade secrets and proprietary information, and have contact with or knowledge of the
Company’s employees and contractors. 
 C. The Company and Employee agree that because of the knowledge, information and
relationships to which Employee will be exposed during the course of Employee’s employment with the Company, it would be harmful to the Company for Employee to compete with the Company or solicit its employees or contractors in the manner
prohibited by this Agreement and that the Company has a legitimate business interest in protecting itself from such competition and solicitation. 

NOW, THEREFORE, in consideration of the foregoing and the mutual promises herein contained and other valuable consideration detailed
below, the parties agree as follows: 
 1. Restrictive Covenants. In order to protect, among other things, the
Company’s business interests, its investments in its drug candidates, drug products, trade secrets and proprietary information, its relationships with its employees and contractors, and its goodwill, Employee agrees to the following covenants
and restrictions: 
  1.1 Non-Competition Agreement. During employment with the Company and for a
period of six (6) months after termination of employment with the Company (the “Non-Compete Restricted Period”), Employee will not, directly or indirectly, participate or engage in any business or activity that competes with the Business
of the Company in the Territory (as defined below) in any capacity whatsoever, whether as an individual on his or her own account or as an employee, consultant, contractor, officer, director, 

 
shareholder, partner, member, joint venturer, representative, agent or equity owner of any business entity. Notwithstanding the foregoing, nothing in this Agreement is intended to prohibit
Employee from: 
 (a) being employed by or providing any services to a pharmaceutical, biotechnology, medical
device or other business entity so long as Employee does not perform any work or consulting services for any such entity that, directly or indirectly, relates to any drug candidates or drug products that compete with any drug candidates or drug
products that are then being, or are proposed to be, developed, produced, manufactured, commercialized, provided or marketed by, under or through the Company, any collaborator or licensee of the Company, or other third party under or pursuant to any
agreement or arrangement with the Company, or its or their successors or assigns; or 
 (b) passively owning two
percent (2%) or less of the outstanding equity interests of any privately- or publicly-held entity. 

1.2 Non-Solicitation of Employees. During employment with the Company and for a period of one year after
termination of employment with the Company (the “Non-Solicit Restricted Period”), Employee also will not, directly or indirectly, in any manner, (a) solicit, hire, or offer to hire any employee or contractor of the Company while that
person is employed or engaged by the Company and for three (3) months after the termination of that person’s employment or engagement with the Company, or (b) otherwise encourage or induce any such employee or contractor to
discontinue his or her relationship with the Company. 
  1.3 Nondisparagement. During and at all
times after employment with the Company, Employee further agrees not to make disparaging statements, remarks or rumors about the Company, its parent company, officers, directors, shareholders, employees, contractors, and/or other representatives or
the Company’s Business to any third parties; provided, however, that nothing in this Agreement is intended to prohibit Employee from responding in a truthful and appropriate manner in any legal process or to give truthful and appropriate
testimony in a legal proceeding. 
 2. Consideration. The Company and Employee acknowledge that Employee has received
good and valuable consideration for Employee’s commitment to be bound by the restrictions set forth in this Agreement, which consideration includes, but is not limited to Employee’s initial employment with the Company and all of the
compensation and other benefits therewith. 
 3. Territory. The restrictions contained in Section 1.1 of this
Agreement apply to the following geographic regions: (a) worldwide, in all areas of the world in which the Company conducts or engages in the Business; (b) or, if the foregoing territory is deemed too broad, then all areas of the Americas,
Europe and Asia in which the Company conducts or engages in the Business; (c) or, if the foregoing territory is deemed 
  

   2 

 
too broad, then all areas of the Americas and Europe in which the Company conducts or engages in the Business; (d) or, if the foregoing territory is deemed too broad, then all areas in the
Americas in which the Company conducts or engages in the Business; (e) or, if the foregoing territory is deemed too broad, then all areas in North America in which the Company conducts or engages in the Business; (f) or, if the foregoing
territory is deemed to broad, then all areas in the United States in which the Company conducts or engages in the Business; (g) or, if the foregoing territory is deemed to broad, then all areas in each state of the United States in which the
Company conducts or engages in the Business; (h) or, if the foregoing territory is deemed to broad, then each county, parish or other similar locality of each state in the United States in which the Company conducts or engages in the Business
(herein, the “Territory”). Employee acknowledges that, because the Company engages in the Business worldwide and because Employee could compete with the Company from anywhere in the world, the Territory must be so broadly defined.

 4. Remedies; Extension of Restricted Periods. Employee acknowledges and agrees that the covenants set forth in this
Agreement are reasonable and necessary for the protection of the Company’s legitimate business interests, that irreparable injury will result to the Company if Employee breaches any of the terms of this Agreement and that, in the event Employee
breaches or threatens to breach any provision of this Agreement, the Company will have no adequate remedy at law. Employee accordingly agrees that in the event Employee breaches or threatens to breach any of the covenants set forth herein, the
Company shall be entitled to immediate, temporary and permanent injunctive or other equitable relief without bond and without the necessity of showing actual money damages, subject to a hearing as soon as possible. Employee further agrees that the
Company shall also be entitled to pursue, separately or concurrently, any other remedies available for such breach by Employee, including the recovery of any damages it is able to prove. Employee further agrees that the Non-Compete Restricted Period
and the Non-Solicit Restricted Period will each be extended for a period of time equal to any period during which Employee is in breach of Section 1.1 or Section 1.2 hereof, as the case may be, and/or any period of time during which
Employee and the Company are engaged in litigation arising from or related to Sections 1.1 or 1.2 hereof, as the case may be. 

5. Enforcement. Employee agrees that, if a court of competent jurisdiction determines, contrary to the Agreement of the parties,
that any portion of this Agreement is unreasonable, invalid, overbroad or unenforceable, the remainder of the Agreement shall be given full effect without regard to the invalid provisions and the Company may enforce the covenant as to any lesser
portion of the activity, Non-Compete Restricted Period, Non-Solicit Restricted Period and/or Territory that is deemed by the court to be reasonable and enforceable under applicable law. In this regard, the covenants shall be divisible as to
activity, Non-Compete Restricted Period, Non-Solicit Restricted Period and/or Territory, with each month deemed to be a separate period of time, and each state and country, or part thereof included in the Territory, deemed to be a separate
geographic area. Employee further agrees that the Company may, at its option, seek to enforce the covenant as to any lesser activity, Non-Compete Restricted Period, Non-Solicit Restricted Period and/or Territory that the Company deems appropriate.

  

 3 

 6. Effect of Termination. Employee agrees that the terms of this Agreement shall be
enforceable against the Employee regardless of who terminates the employment relationship and regardless of the basis of Employee’s termination, whether voluntary or involuntary and with or without cause. Employee further agrees that the
existence of a claim by Employee against the Company, whether predicated on Employee’s termination, this Agreement or otherwise, shall not constitute a defense to enforcement of the restrictions contained herein. Notwithstanding the foregoing,
in the event the Company terminates Employee’s employment due to a reduction in force or layoff in connection with the discontinuation or cessation of a business line, unit, function or department, the Company shall not enforce Section 1.1
of the Agreement. 
 7. Notification. Employee authorizes the Company to notify others, including but not limited to any
future employer of Employee, about the existence and terms of this Agreement and Employee’s obligations hereunder. 
 8.
Jurisdiction and Venue. The parties agree that the federal or state courts sitting in Wake County, North Carolina, shall be the exclusive jurisdiction to enforce the covenants set forth in this Agreement and to resolve any disputes or
controversies arising out of or related to this Agreement. Employee consents to personal jurisdiction and venue in either of said courts, and waives any claims or defenses based on improper venue or jurisdiction. 

9. Governing Law. This Agreement shall be construed and enforced in accordance with the laws of the State of North Carolina.

 10. Severability. The provisions of this Agreement as well as each paragraph and subparagraph hereof shall be deemed
severable, and if any provisions, paragraphs or subparagraphs hereof are held to be invalid or unenforceable by a court of competent jurisdiction, the remaining provisions, paragraphs and/or subparagraphs shall continue to be valid and enforceable.

 11. Modification. This Agreement cannot be altered, amended, or modified in any respect, except by a writing that
specifically refers to this Agreement and the amendment(s) thereto, duly executed by the parties. 
 12. Waiver. The
Company’s waiver of any violation of this Agreement or failure to enforce any provision of this Agreement shall not constitute a waiver of the Company’s rights with respect to other or future violations of this Agreement. Any waiver must
be in a writing signed by the Company and specifically refer to a waiver of provision(s) of this Agreement. 
 13. Binding
Effect. This Agreement shall be binding upon and inure to the benefit of the parties, their heirs, successors and assigns. 

14. Entire Agreement. This Agreement contains the entire agreement of the parties with respect to the matters set forth herein and
supercedes all previous negotiations and discussions, agreements and understandings regarding such matters, with 
  

 4 

 
the exception of Employee’s Proprietary Information and Inventions Agreement and any employment agreement to which Employee and the Company are parties. In the event of any conflict between
this Agreement and any other the Company agreements, the terms of the agreement which are most restrictive shall control. It is understood that this Agreement does not constitute an express or implied employment contract for any definite period of
time and that, absent a written agreement between the Company and Employee, Employee’s employment with the Company is “at will” meaning that either the Company or Employee can end the employment relationship at any time, with or
without cause. 
 15. Execution in Counterparts. This Agreement may be executed in any number of counterparts, each of
which shall be deemed an original and all of which taken together shall constitute one and the same instrument. 
 IN WITNESS
WHEREOF, the parties have executed this Non-Competition and Non-Solicitation Agreement, effective as of the last date set forth below. 
  

			
	PPD THERAPEUTICS, INC.:
		
	By:	 	 
	Name:	 	 
	Title:	 	 
	Date:	 	 
	
	EMPLOYEE:
	
	  
	Name: Marshall Woodworth
	Date:                          
                                         
                         

 

 5Form of Purchase Agreement

 Exhibit 10.1 

PURCHASE AGREEMENT 
 Ladies and
Gentlemen: 
 The undersigned entities set forth on Schedule I hereto (each an “Investor”), hereby confirm and
agree with you as follows: 
 1.        This Purchase Agreement (the
“Agreement”) is made as of May 13, 2010, by and among Bryn Mawr Bank Corporation, a Pennsylvania corporation (the “Company”) and each Investor. 

2.        The Company has authorized the sale and issuance of up to 1,548,167 shares (the
“Shares”) of the Company’s common stock, $1.00 par value (the “Common Stock”), to certain investors (the “Offering”). The Company has filed with the Securities and Exchange Commission (the “Commission”) a
registration statement on Form S-3 (File No. 333-159588) which became effective on June 17, 2009, covering the registration of the Shares under the Securities Act of 1933, as amended (the “1933 Act”), and the rules and
regulations of the Commission under the 1933 Act. 
 3.        The Company and each
Investor agree that each Investor will purchase from the Company and the Company will issue and sell to each Investor the number of Shares set forth opposite such Investor’s name on Schedule I hereto, at a purchase price per share as set
forth on the signature page hereto, pursuant to the Terms and Conditions for Purchase of Shares attached hereto as Annex I and incorporated herein by reference as if fully set forth herein. Each Investor acknowledges that the offering is not being
underwritten by the placement agents (the “Placement Agents”) named in the General Disclosure Package and the Prospectus (each as defined in Annex I) and that there is no minimum offering amount. Certificates representing the Shares
purchased by each Investor will not be issued to such Investor; instead, such Shares will be credited to each Investor using customary book-entry procedures. 

4.        Each Investor represents that, except as set forth on Schedule II hereto, (a) it
has had no position, office or other material relationship within the past three years with the Company or persons known to it to be affiliates of the Company, (b) it is not a person or account which directly or indirectly owns, is owned by or
is under common ownership with Stifel, Nicolaus & Company, Keefe, Bruyette & Woods, Inc. or Boenning & Scattergood, Inc. as of the date hereof and (c) after giving effect to the Offering, neither the undersigned
Investor nor any group of Investors (as identified in a public filing made with the Commission) of which the undersigned Investor is a part, in connection with the offering of the Shares will acquire, or obtain the right to acquire, 4.9% or more of
the Common Stock (or securities convertible or exercisable for Common Stock) or the voting power of the Company. 

5.        Each Investor hereby confirms receipt of the Company’s base prospectus, dated
June 17, 2009 (the “Basic Prospectus”) distributed by email to each Investor with this Agreement. Each Investor confirms that it had full access to the Basic Prospectus and the information incorporated by reference therein and was
fully able to download, print, read and review such documents. Each investor confirms that it will be able to access the Basic 

 
Prospectus, as supplemented by the prospectus supplement, dated May 14, 2010 (together, the “Prospectus”), filed with the Commission pursuant to Section 424(b) under the 1933
Act. Each Investor acknowledges that it will be required to bear the cost, if any, of printing the Prospectus delivered to it by email. The Prospectus shall not contain any material non-public information other than as it relates to the Offering.

  

 -2- 

 Please confirm that the foregoing correctly sets forth the agreement between us by signing
in the space provided below for that purpose. 
 AGREED AND ACCEPTED: 

 

			
	INVESTOR
	
	 
		
	 By:
	 	  

		
	 Name:
	 	  

			
		
	 Aggregate number of Shares
	 	  

		
	 Price per Share
	 	  

		
	 Aggregate purchase price
	 	  

			
	 BRYN MAWR BANK CORPORATION,

a Pennsylvania corporation

		
	By:	 	  

	Name:	 	Geoffrey L. Halberstadt
	Title:	 	Secretary

  

 -4- 

 SCHEDULE I 

SCHEDULE OF INVESTORS 
  

															
	 Investor
	  	 Name in which

book-entry

should be made

(if different):
	  	 Investor Address, Telephone

and Contact Person
	  	 Aggregate

Number of

Shares
	  	 Aggregate

Purchase Price
	  	 Tax ID Number
	  	 Name of Broker,

Telephone and Contact

Person/Internal Account

Number
	  	DTC Participant
Number of Broker

								
	 1.
	  		  		  		  		  		  		  	
								
	 2.
	  		  		  		  		  		  		  	
								
	 3.
	  		  		  		  		  		  		  	
								
	 4.
	  		  		  		  		  		  		  	
								
	 5.
	  		  		  		  		  		  		  	
								
	 6.
	  		  		  		  		  		  		  	
								
	 7.
	  		  		  		  		  		  		  	
								
	 8.
	  		  		  		  		  		  		  	

  

 Sch. I-1 

 SCHEDULE II 

 

 Sch. II-1 

 ANNEX I 

TERMS AND CONDITIONS FOR PURCHASE OF SHARES 

1.        Authorization and Sale of Shares. The Company has authorized the sale of up to
1,548,167 Shares. The Company reserves the right to increase or decrease this number. 

2.        Agreement to Sell and Purchase the Shares; Subscription Date. 

2.1        Upon the terms and subject to the conditions hereinafter set forth, at
the Closing (as defined in Section 3), the Company will sell to each Investor, and each Investor will purchase from the Company, the number of Shares set forth on Schedule I of this Agreement at the purchase price set forth therein.

 2.2        The Company may enter into agreements similar to this
Agreement with certain other investors (the “Other Investors”) and expects to complete sales of Shares to them and the Company agrees that the agreements with the Other Investors will not contain any terms or provisions more favorable to
such Other Investors than are contained in this Agreement. (Each Investor and the Other Investors are hereinafter collectively referred to as the “Investors,” and this Agreement and the purchase agreements executed by the Other Investors
are hereinafter collectively referred to as the “Agreements”). The Company may accept or reject any one or more Agreements in its sole discretion. 

3.        Delivery of the Shares at Closing. The completion of the purchase and sale of
the Shares (the “Closing”) shall occur on May 18, 2010 at 10:00 a.m. (Eastern Time) or at such later date and time as the parties hereto may agree upon (such date and time of payment being herein called the “Closing Date”),
at the offices of the Placement Agents’ counsel. At the Closing, the Company shall deliver to each Investor, using customary book-entry procedures, the number of Shares set forth on Schedule I to this Agreement, and each Investor shall deliver
to the Company via wire transfer of funds in the full amount of the aggregate purchase price for the Shares being purchased hereunder as set forth opposite such Investor’s name on Schedule I hereto to a bank account designated by the
Company. 
 The Company’s obligation to issue and sell the Shares to each Investor shall be subject to the following
conditions, any one or more of which may be waived by the Company: (a) receipt by the Company of wire transfer of funds in the full amount of the purchase price for the Shares being purchased; (b) completion of the purchases and sales of
Shares under the Agreements that may be executed with the Other Investors; and (c) the accuracy of the representations and warranties made by each Investor and the fulfillment of those undertakings of each Investor to be fulfilled prior to the
Closing. 
 Each Investor’s obligation to purchase the Shares shall be subject to the condition that the Placement Agents
shall not have (a) terminated the Placement Agency Agreement dated as of May 13, 2010 (the “Placement Agency Agreement”) between the Company and the Placement Agents pursuant to the terms thereof or (b) determined that the
conditions to closing in the Placement Agency Agreement have not been satisfied without waiver thereof. 
  

 Annex I-1 

 4.        Representations and Warranties.

 4.1        Representations and Warranties by the Company. The
Company represents and warrants to each Investor as of the date hereof and as of the Closing Date referred to in Section 3 hereof, and agree with the Investor, as follows: 

(a)        Compliance with Registration Requirements. The Company has
filed with the Securities and Exchange Commission (the “Commission”) a registration statement on Form S-3 (File No. 333-159588) under the Securities Act of 1933, as amended (the “1933 Act”), in respect of the Company’s
Common Stock (including the Shares) not earlier than three years prior to the date hereof; such registration statement, and any post-effective amendment thereto, has been declared effective by the Commission; and no stop order suspending the
effectiveness of such registration statement or any part thereof has been issued and no proceeding for that purpose has been initiated or, to the knowledge of the Company, threatened by the Commission and no notice of objection of the Commission to
the use of such form of registration statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the 1933 Act has been received by the Company (the base prospectus filed as part of such registration statement, in the form in
which it has most recently been filed with the Commission on or prior to the date of this Agreement, is hereinafter called the “Basic Prospectus”; the various parts of such registration statement, including all exhibits thereto and any
prospectus supplement relating to the Shares that is filed with the Commission and deemed by virtue of Rule 430B to be part of such registration statement, each as amended at the time such part of the registration statement became effective with
respect to the Placement Agents (the “Effective Date”), are hereinafter collectively called the “Registration Statement”; the prospectus supplement specifically relating to the Shares prepared and filed with the Commission
pursuant to Rule 424(b) under the 1933 Act is hereinafter called the “Prospectus Supplement”; the Basic Prospectus, as amended and supplemented by the Prospectus Supplement, is hereinafter called the “Prospectus”; any reference
herein to the Basic Prospectus, the Prospectus Supplement or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form S-3 under the 1933 Act; any reference to any
amendment or supplement to the Basic Prospectus, the Prospectus Supplement or the Prospectus shall be deemed to refer to and include any post-effective amendment to the Registration Statement, any prospectus supplement relating to the Shares filed
with the Commission pursuant to Rule 424(b) under the 1933 Act and any documents filed under the Securities Exchange Act of 1934, as amended (the “1934 Act”), and incorporated therein, in each case after the date of the Basic Prospectus,
the Prospectus Supplement or the Prospectus, as the case may be; any reference to any amendment to the Registration Statement shall be deemed to refer to and include any annual report of the Company filed pursuant to Section 13(a) or 15(d) of
the 1934 Act after the effective date of the Registration Statement that is incorporated by reference in the Registration Statement; and any “issuer free writing prospectus” as defined in

  

 Annex I-2 

 
Rule 433 under the 1933 Act relating to the Shares is hereinafter called an “Issuer Free Writing Prospectus”). 

On the Effective Date, the Registration Statement complied, and on the date of the Prospectus, the date any
post-effective amendment to the Registration Statement becomes effective, the date any supplement or amendment to the Prospectus is filed with the Commission and the Closing Date, the Registration Statement and the Prospectus (and any amendment
thereof or supplement thereto) will comply, in all material respects, with the requirements of the 1933 Act and the published rules and regulations thereunder (the “Rules”) adopted by the Commission and the 1934 Act and the rules and
regulations of the Commission thereunder. The Registration Statement did not, as of the Effective Date, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make
the statements therein not misleading; and on the Effective Date and the other dates referred to in the second sentence of this paragraph 4.1(a), neither the Registration Statement nor any amendment thereof or supplement thereto, contained or will
contain any untrue statement of a material fact or will omit to state any material fact required to be stated therein or necessary in order to make the statements therein not misleading. 

No order preventing or suspending the use of the Basic Prospectus, the Prospectus Supplement, the Prospectus or any
Issuer Free Writing Prospectus has been issued by the Commission, and the Basic Prospectus and the Prospectus Supplement, at the time of filing thereof, conformed in all material respects to the requirements of the 1933 Act and the Rules and did not
contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. 

For the purposes of this Agreement, the “Applicable Time” means, with respect to any Shares, the time of
Investor’s delivery of a signed copy of this Agreement; the Basic Prospectus and the applicable Issuer Free Writing Prospectus(es) issued at or prior to such Applicable Time, taken together (collectively, and, with respect to any Shares,
together with the public offering price of such Shares and the aggregate number of Shares up to which the Company will offer, the “General Disclosure Package”) as of each Applicable Time and the Closing Date, did not and will not include
any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and each applicable Issuer Free Writing
Prospectus will not conflict with the information contained in the Registration Statement, the Prospectus Supplement or the Prospectus and each such Issuer Free Writing Prospectus, as supplemented by and taken together with the General Disclosure
Package as of such Applicable Time, will not include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading. 
  

 Annex I-3 

 The representations and warranties in this Section 4(a) shall not
relate to any written information furnished to the Company by the Placement Agents expressly for use in the Prospectus (it being understood that no such information has been provided by the Placement Agents). 

(b)        Incorporation of Documents by Reference. The documents
incorporated or deemed to be incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, when they became effective or were filed with the Commission, as the case may be, complied in all material
respects with the requirements of the 1934 Act and the rules and regulations of the Commission thereunder, and, when read together with the other information in the General Disclosure Package and the Prospectus, (a) at and as of the time the
Registration Statement became effective, (b) at and as of the Applicable Time, (c) at and as of the time the Prospectus was issued and (d) at the Closing Date, as applicable, did not and will not contain an untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. 

(c)        Financial Statements. The financial statements included or
incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, together with the related schedules and notes, present fairly, in all material respects, the financial position of the Company and its
consolidated subsidiaries at the dates indicated and the statement of operations, shareholders’ equity and cash flows of the Company and its consolidated subsidiaries for the periods specified; said financial statements have been prepared in
conformity with generally accepted accounting principles in the United States (“GAAP”) applied on a consistent basis throughout the periods involved. The supporting schedules, if any, present fairly, in all material respects, in accordance
with GAAP the information required to be stated therein. The selected financial data and the summary financial information included in each of the General Disclosure Package and the Prospectus present fairly, in all material respects, the
information shown therein and have been compiled on a basis consistent with that of the audited financial statements included or incorporated by reference in the Registration Statement. All disclosures contained in the Registration Statement, the
General Disclosure Package or the Prospectus, or incorporated by reference therein, regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations of the Commission) comply with Regulation G of the 1934 Act
and Item 10 of Regulation S-K of the 1933 Act, to the extent applicable. 

(d)        No Material Adverse Change in Business. Since the respective
dates as of which information is given in the Registration Statement or the General Disclosure Package or the Prospectus, except as otherwise stated therein, (A) there has been no material adverse change, or any development that could
reasonably be expected to cause a material adverse change, in the financial condition, or in the earnings, business affairs or business prospects of the Company and its consolidated direct or indirect subsidiaries considered as one

  

 Annex I-4 

 
enterprise, whether or not arising in the ordinary course of business (a “Material Adverse Effect”), (B) there have been no transactions entered into by the Company or any of its
consolidated direct or indirect subsidiaries, other than those in the ordinary course of business, which are material with respect to the Company and its direct or indirect subsidiaries considered as one enterprise, and (C) except for cash and
stock dividends on the Common Stock as described in each of the Registration Statement, the General Disclosure Package and the Prospectus in amounts per share that are consistent with past practice, there has been no dividend or distribution of any
kind declared, paid or made by the Company on any class of its capital stock. 

(e)        Good Standing of the Company. The Company has been duly
organized and is validly existing as a corporation in good standing under the laws of the jurisdiction of its organization and has corporate power and authority to own, lease and operate its properties and to conduct its business as described in
each of the General Disclosure Package and the Prospectus and to enter into and perform its obligations under this Agreement; and the Company is duly qualified as a foreign corporation to transact business and is in good standing in each other
jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure so to qualify or to be in good standing would not result in a Material Adverse
Effect. The Company is duly registered as a bank holding company under the Bank Holding Company Act of 1956, as amended (the “BHCA”). 

(f)        Authorization and Description of Shares. The Shares have been
duly authorized and reserved for issuance and sale pursuant to this Agreement and, when issued and delivered by the Company pursuant to this Agreement against payment of the consideration set forth herein, will be validly issued and fully paid and
non-assessable; the Common Stock conforms to all statements relating thereto contained in each of the General Disclosure Package and the Prospectus in all material respects and such description conforms to the rights set forth in the Articles of
Incorporation of the Company; no holder of the Shares will be subject to personal liability by reason of being such a holder; and the issuance of the Shares is not subject to the preemptive or other similar rights of any securityholder of the
Company. 
 (g)        Listing. The Company’s Common Stock
has been registered pursuant to Section 12(b) of the 1934 Act and is listed on the NASDAQ Global Select Market (“NASDAQ”), and the Company has taken no action designed to, or likely to have the effect of, terminating the registration
or listing of the Common Stock from NASDAQ, nor has the Company received any notification that the Commission or NASDAQ is contemplating terminating such registration or listing. The outstanding shares of the Common Stock have been approved for
listing and at the Closing Date the Shares being sold hereunder shall have been approved for listing, subject only to official notice of issuance, on NASDAQ. 
  

 Annex I-5 

 (h)        Regulation M
Compliance. The Company has not, and to its actual knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any
security of the Company to facilitate the sale or resale of any of the Shares, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Shares, or (iii) paid or agreed to pay to any person any
compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company’s placement agents in connection with the placement of the Shares,
compensation paid in connection with certain issuances of the Company’s Common Stock under its Dividend Reinvestment and Stock Purchase Plan, or as disclosed in the Company’s reports, schedules, forms, statements and other documents
required to be filed by it under the 1934 Act, including pursuant to Section 13(a) or 15(d) thereof. 

(i)        Disclosure. Except with respect to the material terms and
conditions of the Offering, the Company confirms that neither it nor any other person acting on its behalf has provided any of the Investors or their agents or counsel with any information that it believes constitutes or might constitute material,
non-public information. The Company understands and confirms that the Investors will rely on the foregoing representation in effecting transactions in securities of the Company. 

5.        Representations, Warranties and Covenants of each Investor. Each Investor
represents and warrants to the Company as of the date hereof and as of the Closing Date referred to in Section 3 hereof, and agree with the Company, as follows: 

5.1        Each Investor represents and warrants that it has received and read
the Company’s General Disclosure Package and, only as of the Closing Date, the Prospectus. 

5.2        Each Investor, if outside the United States, will comply with all
applicable laws and regulations in each foreign jurisdiction in which it purchases, offers, sells or delivers Shares or has in its possession or distributes any offering material, in all cases at its own expense. 

5.3        Each Investor further represents and warrants to, and covenants with,
the Company that (i) such Investor has full right, power, authority and capacity to enter into this Agreement and to consummate the transactions contemplated hereby and has taken all necessary action to authorize the execution, delivery and
performance of this Agreement, and (ii) this Agreement constitutes a valid and binding obligation of such Investor, enforceable in accordance with its terms, except as affected by bankruptcy, insolvency, fraudulent conveyance, reorganization,
moratorium and other similar laws relating to or affecting creditors’ rights generally, general equitable principles (whether considered in a proceeding in equity or at law) and an implied covenant of good faith and fair dealing and except as
rights to indemnification or contribution thereunder may be limited by federal or state laws. 
  

 Annex I-6 

 5.4        Each Investor understands
the Company has not provided it with any legal, tax or investment advice in connection with its purchase of Shares. Such Investor has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or
appropriate in connection with its purchase of Shares. 

5.5        From and after obtaining the knowledge of the sale of the Shares
contemplated hereby, such Investor has not taken, and prior to the public announcement of the transaction such Investor shall not take, any action that has caused or will cause such Investor to have, directly or indirectly, sold or agreed to sell
any shares of Common Stock, effected any short sale, whether or not against the box, established any “put equivalent position” (as defined in Rule 16a-1(h) under the 1934 Act) with respect to the Common Stock, granted any other right
(including, without limitation, any put or call option) with respect to the Common Stock or with respect to any security that includes, relates to or derives any significant part of its value from the Common Stock, whether or not, directly or
indirectly, in order to hedge its position in the Shares. 
 6.        Securities
Laws Disclosure; Publicity. The Company shall, by 9:30 a.m. (New York City time) on the business day following the date hereof issue a press release disclosing the material terms of the transactions contemplated hereby and, by 5:30 p.m. (New
York City time) on May 17, 2010, file a Current Report on Form 8-K disclosing the material terms of the transactions contemplated hereby and including the form of the Agreement as exhibits thereto. From and after the issuance of the press
release, the Company shall have publicly disclosed all material, non-public information delivered to any of the Investors by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents in connection
with the Offering. The Company shall not disclose the name of the Investor or its investment adviser in any press release or other public statement about the Offering, except if such disclosure is required by law, in which case the Company shall
promptly provide the other party with prior notice of such public statement or communication. 

7.        Survival of Representations, Warranties and Agreements. Notwithstanding any
investigation made by any party to this Agreement, all covenants, agreements, representations and warranties made by the Company and each Investor herein shall survive the execution of this Agreement, the delivery to such Investor of the Shares
being purchased and the payment therefor for a period of one year. 

8.        Notices. All notices, requests, consents and other communications hereunder
shall be in writing, shall be mailed (A) if within domestic United States by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, or by facsimile, or (B) if delivered from
outside the United States, by International Federal Express or facsimile, and shall be deemed given (i) if delivered by first-class registered or certified mail domestic, three business days after so mailed, (ii) if delivered by a
nationally recognized overnight carrier, one business day after so mailed, (iii) if delivered by International Federal Express, two business days after so mailed, (iv) if delivered by facsimile, upon electronic confirmation of receipt and
shall be delivered as addressed as follows: 
 if to the Company, to: 

 

 Annex I-7 

 Bryn Mawr Bank Corporation 

801 Lancaster Avenue 

Bryn Mawr, PA 19010 

Fax No. (610) 525-3687 

Attention:. Frederick C. Peters II 
  

if to an Investor, at its address on Schedule I hereto, or at such other address or addresses as may have been furnished to the
Company in writing. 
 9.        Changes. This Agreement may not be modified or
amended except pursuant to an instrument in writing signed by the Company and each Investor. 

10.        Headings. The headings of the various sections of this Agreement have been
inserted for convenience or reference only and shall not be deemed to be part of this Agreement. 

11.        Severability. In case any provision contained in this Agreement should be
invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. 

12.        Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE
WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED IN SAID STATE. 

13.        Counterparts. This Agreement may be executed in two or more counterparts, each
of which shall constitute an original, but all of which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties.

 14.        Entire Agreement. This Agreement contains the entire understanding
of the parties hereto with regard to the subject matter contained herein. 
  

 Annex I-8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00173-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00173-of-00352.parquet"}]]